Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults
Completed · Phase 1 · Has a placebo group
Conditions studied: HIV Infection
In brief
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGT121 monoclonal antibody for HIV prevention and therapy.
Key facts
- Study ID
- NCT02960581
- Run by
- International AIDS Vaccine Initiative
- People needed
- 48
- Starts
- 2016-11-01
- Expected to finish
- 2019-07-08
- Last updated by the study team
- 2019-09-17
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.